CA2264963A1 - Protein markers for esophageal cancer - Google Patents

Protein markers for esophageal cancer

Info

Publication number
CA2264963A1
CA2264963A1 CA002264963A CA2264963A CA2264963A1 CA 2264963 A1 CA2264963 A1 CA 2264963A1 CA 002264963 A CA002264963 A CA 002264963A CA 2264963 A CA2264963 A CA 2264963A CA 2264963 A1 CA2264963 A1 CA 2264963A1
Authority
CA
Canada
Prior art keywords
ipg
ief
protein
esophageal
esophageal cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002264963A
Other languages
French (fr)
Other versions
CA2264963C (en
Inventor
Samir M. Hanash
David G. Beer
Rork Kuick
Robert Hinderer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2264963A1 publication Critical patent/CA2264963A1/en
Application granted granted Critical
Publication of CA2264963C publication Critical patent/CA2264963C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Computerized analysis of 2-D gels, both carrier ampholyte (CA) and immobilized pH gradient (IPG) based, of the proteins in tissue from esophageal tumors, reveals proteins which are different in tumor and control tissue.

Claims (5)

1. An isolated human protein which is overexpressed in esophageal tumors compared to normal esophageal tissue, wherein the protein is selected from the group consisting of IPG 29, IPG 56, IPG 57, IPG 53, IPG 51, IPG 15, IEF 5, IEF 15, IEF 29, IEF 31 and IEF 51.
2. An antibody or antigen binding fragment thereof which specifically binds a protein of claim 1.
3. A method of diagnosing or monitoring the progression of esophageal cancer, comprising:
1) determining the amount of at least one protein in a sample from the patient which protein is overexpressed in esophageal tumors compared to normal esophageal tissue, wherein the protein is selected from the group consisting of IPG 29, IPG 56, IPG 57, IPG 53, IPG 51, IPG 15, IEF 5, IEF 15, IEF 29, IEF 31 and IEF 51; and 2) correlating the amount of the protein with the presence or stage of the disease.
4. The method of claim 3, wherein the determining step comprises an immunological assay.
5. An isolated gene encoding the protein of claim 1.
CA002264963A 1996-05-30 1997-05-29 Protein markers for esophageal cancer Expired - Fee Related CA2264963C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1865996P 1996-05-30 1996-05-30
US60/018,659 1996-05-30
PCT/US1997/008656 WO1997045445A1 (en) 1996-05-30 1997-05-29 Protein markers for esophageal cancer

Publications (2)

Publication Number Publication Date
CA2264963A1 true CA2264963A1 (en) 1997-12-04
CA2264963C CA2264963C (en) 2010-03-09

Family

ID=21789115

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002264963A Expired - Fee Related CA2264963C (en) 1996-05-30 1997-05-29 Protein markers for esophageal cancer

Country Status (10)

Country Link
EP (1) EP0950062B1 (en)
JP (1) JP4993799B2 (en)
AT (1) ATE323103T1 (en)
AU (1) AU739306B2 (en)
CA (1) CA2264963C (en)
DE (1) DE69735676T2 (en)
DK (1) DK0950062T3 (en)
ES (1) ES2258278T3 (en)
NZ (1) NZ333075A (en)
WO (1) WO1997045445A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002951153A0 (en) * 2002-09-02 2002-09-19 Proteome Systems Intellectual Property Pty Ltd An electrophoresis gel having improved swelling properties
JPWO2005093063A1 (en) * 2004-03-29 2008-02-14 株式会社医学生物学研究所 Solid cancer diagnostic kit and pharmaceutical for solid cancer treatment
US8222393B2 (en) 2004-06-02 2012-07-17 Tss Biotech Inc. Polypeptide useful for cancer diagnosis and treatment
GB0521521D0 (en) * 2005-10-21 2005-11-30 Medical Res Council Diagnostic methods and kits
EP2295564A4 (en) 2008-05-21 2011-08-10 Toray Industries Composition and method for determination of esophageal cancer

Also Published As

Publication number Publication date
WO1997045445A1 (en) 1997-12-04
AU3208997A (en) 1998-01-05
EP0950062A1 (en) 1999-10-20
ATE323103T1 (en) 2006-04-15
EP0950062A4 (en) 2000-07-05
NZ333075A (en) 2000-05-26
JP2000511536A (en) 2000-09-05
DE69735676T2 (en) 2006-10-19
ES2258278T3 (en) 2006-08-16
JP4993799B2 (en) 2012-08-08
AU739306B2 (en) 2001-10-11
DK0950062T3 (en) 2006-08-14
DE69735676D1 (en) 2006-05-24
EP0950062B1 (en) 2006-04-12
CA2264963C (en) 2010-03-09

Similar Documents

Publication Publication Date Title
CA2280930A1 (en) Protein markers for lung cancer and use thereof
WO1998035985B1 (en) Protein markers for lung cancer and use thereof
US20140080736A1 (en) Tumour marker proteins and uses thereof
EP1731619A3 (en) Tumour markers
EP1125134B1 (en) S100 proteins and autoantibodies as serum markers for cancer
WO2010114514A1 (en) Detection of fibrin and fibrinogen degradation products and associated methods of production and use for the detection and monitoring of cancer
CN111273012A (en) Method for combined detection of serum autoantibodies
Shin et al. Proteomics approaches to uncover the repertoire of circulating biomarkers for breast cancer
CA2264963A1 (en) Protein markers for esophageal cancer
WO2000032635A3 (en) Tumor specific human monoclonal antibodies and methods of use
DE69823660D1 (en) METHOD FOR IDENTIFYING TUMORANTIGENS WITH AUTOANTIBODIES IN SERUM
US6759204B2 (en) Method and kit for early diagnosis of cancer
US7078176B2 (en) Detection and quantification of Cripto-1
US20100248269A1 (en) Detection of fibrin and fibrinogen degradation products and associated methods of production and use for the detection and monitoring of cancer
EP1796723B1 (en) Method of diagnosing cancer by detecting the expression of spag9 or the presence of anti-spag9 antibodies
Mirowski et al. Serological and immunohistochemical detection of a 65-kDa oncofetal protein in breast cancer
US20040005645A1 (en) Protein markers for esophageal cancer
AU2004201392B2 (en) S100 proteins and autoantibodies as serum markers for cancer
KR100991289B1 (en) Autoantibody marker of alpha2-hs-glycoprotein and diagnosis kit for breast cancer
Ohkawa et al. An improved sensitive assay method for the heterogeneity of α-foetoprotein: possible application for early differential diagnosis
Wang et al. Proteomics Approaches to Uncover the Repertoire of Circulating Biomarkers for Breast Cancer

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20160530